Maze Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Maze Therapeutics Q2 net loss widens, misses estimates on higher R&D expenses
Maze Therapeutics posts smaller than expected Q1 loss
U.S. STOCKS ON THE MOVE-Tesla, AT&T, Yesway
Maze Therapeutics jumps on $150 mln share offering for kidney disease drugs
Brief: Maze Therapeutics Announces $150 Million Registered Offering
U.S. RESEARCH ROUNDUP-Dutch Bros, Phreesia, Starbucks
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta
U.S. STOCKS ON THE MOVE-Arm, Destiny Tech100, Terns Pharma
Maze Therapeutics rises as kidney disease drug shows positive results in trial
Maze Therapeutics reports bigger-than-expected Q4 loss on higher R&D costs
U.S. RESEARCH ROUNDUP-Carmax, Mirion Technologies, Valmont Industries
U.S. STOCKS ON THE MOVE-Opendoor Technologies, AIRO Group, Camurus
U.S. STOCKS ON THE MOVE-Opendoor Technologies, AIRO Group, Camurus
U.S. STOCKS ON THE MOVE -Apple, Enovix, Kroger
Maze Therapeutics jumps on early data for kidney disease drug
Brief: Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement